Genomic risk scores, biomolecules, and clinical conditions to predict atrial fibrillation: time to integrate what we can measure.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

1. Arrhythmias and Sudden Death: What is New in Hypertrophic Cardiomyopathy?Cardiac failure review · 2025
   Review
2. Blood urea nitrogen to serum albumin ratio as a prognostic marker for 28-day mortality in atrial fibrillation: a retrospective cohort study.Frontiers in cardiovascular medicine · 2025
   Article
3. The burden of atrial fibrillation/atrial flutter in Europe from 1990 to 2021, with a forecast of incidence through 2044.Frontiers in cardiovascular medicine · 2025
   Article

Corrections and comments

• Comment on
  A polygenic risk score predicts atrial fibrillation in cardiovascular disease.2023

Authors and funding

3 authors at 3 institutions in 3 countries.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as